Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 9;5(8):e02187.
doi: 10.1016/j.heliyon.2019.e02187. eCollection 2019 Aug.

Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospective review of clinical use

Steven R D Best  1 , Dan G Pavel  2 , Natalie Haustrup  3
Affiliations

Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospective review of clinical use

Steven R D Best et al. Heliyon. .

Abstract

Background: Both transcranial magnetic stimulation (TMS) and infused ketamine are recognized treatments for patients suffering from major depressive disorder (MDD). A novel therapy named combination TMS with ketamine (CTK) is introduced. This retrospective review examined the safety and clinical benefits of CTK in patients suffering from treatment-resistant depression (TRD) during the routine practice of psychiatry in a private clinic.

Methods: TRD patients (N = 28) received a coincident application of high-output TMS (30 minutes) with biomarker-determined ketamine infusions (20 minutes). Frequency of treatment was dependent on patient responsiveness (10-30 sessions). Clinical global impression (CGI) data was collected pre- and post-treatment and then two years later.

Results: The mean reduction in CGI severity for the patient group following CTK was 4.46 ± 0.54 at a 99% confidence interval and was deemed statistically significant using a paired t-test (α = 0.01, t = 22.81 p < 0.0001). This reduction was sustained for two years following treatment completion and this remission was deemed statistically significant by a second paired t-test (α = 0.01, t = 27.36, p < 0.0001).

Limitations: Retrospective review of a limited number of patients undergoing CTK in a clinical practice.

Conclusions: This clinical review indicated that CTK is an effective, long-term therapy (after two years) and can be used for TRD patients. The coincident administration of ketamine allowed for higher TMS intensities than otherwise would be tolerated by patients. Further studies for optimization of CTK are warranted.

Keywords: Biomarker; Combination; Comorbidity; Depression; Ketamine; Neurology; Psychiatry; TMS.

PubMed Disclaimer

Figures

Figure 1
Fig. 1
Mean CGI-S score of sample group at times representing pre-treatment (T1), post-treatment (T2) and two years following treatment completion (T3). Bars represent respective standard deviations. Statistical significance of CTK efficacy was tested using paired t-tests. Statistically significant reduction in CGI-S following treatment (T1→T2: α = 0.01, t = 22.81 p < 0.0001), which was sustained for 2 years following treatment (T2→T3: α = 0.01, t = 27.36, p <0.0001).
See this image and copyright information in PMC

References

    1. Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J. Clin. Psychiatry. 2017;78(7):852–857. - PubMed
    1. Baeken C., De Raedt R. Neurobiological mechanisms of repetitive transcranial magnetic stimulation on the underlying neurocircuitry in unipolar depression. Dialogues Clin. Neurosci. 2011;13(1):139–145. - PMC - PubMed
    1. Berlim M.T. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol. Med. 2014;44(2):225–239. - PubMed
    1. Berman R.M. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry. 2000;47(4):351–354. - PubMed
    1. Best S.R.D. Rapid relief of treatment resistant depression by facilitated ketamine infusion: a preliminary report. Act. Nerv. Super. 2014;56(1–2):28–36.